YKL-39 does not work directly on tumor cells but can influence tumor progression by altering the state of the TME, and elevated YKL-39 levels are associated with increased risk of metastasis and post-chemotherapy drug resistance in breast cancer [21]. Here, CHI3L2 is linked to neoplasm.